HEADER APOPTOSIS 18-MAY-11 2YJ1 TITLE PUMA BH3 FOLDAMER IN COMPLEX WITH BCL-XL COMPND MOL_ID: 1; COMPND 2 MOLECULE: BCL-2-LIKE PROTEIN 1; COMPND 3 CHAIN: A, C; COMPND 4 FRAGMENT: RESIDUES 1-26,83-209; COMPND 5 SYNONYM: BCL2-L-1, APOPTOSIS REGULATOR BCL-X BCL-XL; COMPND 6 ENGINEERED: YES; COMPND 7 MOL_ID: 2; COMPND 8 MOLECULE: ALPHA-BETA-PUMA BH3 FOLDAMER; COMPND 9 CHAIN: B, D; COMPND 10 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 9 EXPRESSION_SYSTEM_VECTOR: PGEX; SOURCE 10 MOL_ID: 2; SOURCE 11 SYNTHETIC: YES; SOURCE 12 ORGANISM_SCIENTIFIC: SYNTHETIC CONSTRUCT; SOURCE 13 ORGANISM_TAXID: 32630 KEYWDS APOPTOSIS, MEMBRANE PROTEIN, FOLDAMER, BH3 DOMAIN, AUTOPHAGY EXPDTA X-RAY DIFFRACTION AUTHOR E.F.LEE,B.J.SMITH,W.S.HORNE,K.N.MAYER,M.EVANGELISTA,P.M.COLMAN, AUTHOR 2 S.H.GELLMAN,W.D.FAIRLIE REVDAT 6 15-MAY-24 2YJ1 1 REMARK REVDAT 5 20-DEC-23 2YJ1 1 REMARK REVDAT 4 15-NOV-23 2YJ1 1 LINK ATOM REVDAT 3 10-JUL-19 2YJ1 1 REMARK REVDAT 2 24-APR-19 2YJ1 1 REMARK SEQRES LINK REVDAT 1 12-OCT-11 2YJ1 0 JRNL AUTH E.F.LEE,B.J.SMITH,W.S.HORNE,K.N.MAYER,M.EVANGELISTA, JRNL AUTH 2 P.M.COLMAN,S.H.GELLMAN,W.D.FAIRLIE JRNL TITL STRUCTURAL BASIS OF BCL-XL RECOGNITION BY A BH3-MIMETIC JRNL TITL 2 ALPHA-BETA-PEPTIDE GENERATED VIA SEQUENCE-BASED DESIGN JRNL REF CHEMBIOCHEM V. 12 2025 2011 JRNL REFN ISSN 1439-4227 JRNL PMID 21744457 JRNL DOI 10.1002/CBIC.201100314 REMARK 2 REMARK 2 RESOLUTION. 2.24 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX (PHENIX.REFINE) REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : ML REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.24 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 45.44 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.350 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.3 REMARK 3 NUMBER OF REFLECTIONS : 15803 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.194 REMARK 3 R VALUE (WORKING SET) : 0.190 REMARK 3 FREE R VALUE : 0.253 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT : 787 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 45.4484 - 4.0680 0.99 2659 119 0.2165 0.2599 REMARK 3 2 4.0680 - 3.2292 1.00 2526 129 0.1583 0.2037 REMARK 3 3 3.2292 - 2.8211 1.00 2476 145 0.1819 0.2676 REMARK 3 4 2.8211 - 2.5632 1.00 2483 139 0.1863 0.2635 REMARK 3 5 2.5632 - 2.3795 1.00 2468 125 0.1954 0.2820 REMARK 3 6 2.3795 - 2.2392 0.97 2404 130 0.1974 0.2930 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : FLAT BULK SOLVENT MODEL REMARK 3 SOLVENT RADIUS : 1.20 REMARK 3 SHRINKAGE RADIUS : 0.95 REMARK 3 K_SOL : 0.44 REMARK 3 B_SOL : 55.64 REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.210 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 23.880 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 29.22 REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -3.65500 REMARK 3 B22 (A**2) : 0.54770 REMARK 3 B33 (A**2) : 3.10730 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.008 2758 REMARK 3 ANGLE : 1.164 3725 REMARK 3 CHIRALITY : 0.080 384 REMARK 3 PLANARITY : 0.004 484 REMARK 3 DIHEDRAL : 19.642 1047 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2YJ1 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 18-MAY-11. REMARK 100 THE DEPOSITION ID IS D_1290048279. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 05-NOV-09 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 7.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : AUSTRALIAN SYNCHROTRON REMARK 200 BEAMLINE : MX2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.953692 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 15846 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.240 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.4 REMARK 200 DATA REDUNDANCY : 8.700 REMARK 200 R MERGE (I) : 0.18000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 14.2000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.24 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.32 REMARK 200 COMPLETENESS FOR SHELL (%) : 97.1 REMARK 200 DATA REDUNDANCY IN SHELL : 4.80 REMARK 200 R MERGE FOR SHELL (I) : 0.52000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 3.300 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER FOR MR REMARK 200 STARTING MODEL: PDB ENTRY 2P1L REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 38.15 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 1.99 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.05 M CADMIUM SULPHATE 1.0 M SODIUM REMARK 280 ACETATE 0.1 M HEPES PH 7.5. REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 29.45900 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 37.80250 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 35.69100 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 37.80250 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 29.45900 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 35.69100 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TETRAMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: TETRAMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 11080 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 15070 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -56.8 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B, C, D REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 SER A 203 REMARK 465 ARG A 204 REMARK 465 LYS A 205 REMARK 465 GLY A 206 REMARK 465 GLN A 207 REMARK 465 GLU A 208 REMARK 465 ARG A 209 REMARK 465 ACE B 85 REMARK 465 GLY C -4 REMARK 465 PRO C -3 REMARK 465 LEU C -2 REMARK 465 GLY C -1 REMARK 465 SER C 0 REMARK 465 ASN C 197 REMARK 465 ASN C 198 REMARK 465 ALA C 199 REMARK 465 ALA C 200 REMARK 465 ALA C 201 REMARK 465 GLU C 202 REMARK 465 SER C 203 REMARK 465 ARG C 204 REMARK 465 LYS C 205 REMARK 465 GLY C 206 REMARK 465 GLN C 207 REMARK 465 GLU C 208 REMARK 465 ARG C 209 REMARK 465 NH2 D 107 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLN A 3 CD REMARK 470 GLN A 121 CD REMARK 470 GLU A 158 CD REMARK 470 GLU C 92 OE2 REMARK 470 GLU C 124 CD OE1 OE2 REMARK 470 GLU C 193 CD OE1 OE2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 HR7 B 96 -77.84 -11.19 REMARK 500 HR7 D 96 -79.10 -11.33 REMARK 500 TYR D 105 56.59 -101.68 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 B3E B 89 ILE B 90 144.89 REMARK 500 B3Q B 93 LEU B 94 141.94 REMARK 500 ARG B 95 HR7 B 96 139.62 REMARK 500 B3D B 100 LEU B 101 142.58 REMARK 500 B3A B 103 GLN B 104 144.85 REMARK 500 B3E D 89 ILE D 90 141.73 REMARK 500 B3Q D 93 LEU D 94 141.33 REMARK 500 ARG D 95 HR7 D 96 136.41 REMARK 500 B3D D 100 LEU D 101 146.71 REMARK 500 B3A D 103 GLN D 104 140.50 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: MAIN CHAIN PLANARITY REMARK 500 REMARK 500 THE FOLLOWING RESIDUES HAVE A PSEUDO PLANARITY REMARK 500 TORSION ANGLE, C(I) - CA(I) - N(I+1) - O(I), GREATER REMARK 500 10.0 DEGREES. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 500 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 500 I=INSERTION CODE). REMARK 500 REMARK 500 M RES CSSEQI ANGLE REMARK 500 B3E B 89 -18.36 REMARK 500 B3Q B 93 -18.56 REMARK 500 B3D B 100 -19.07 REMARK 500 B3A B 103 -17.67 REMARK 500 B3E D 89 -19.70 REMARK 500 B3Q D 93 -20.20 REMARK 500 B3D D 100 -16.85 REMARK 500 B3A D 103 -19.81 REMARK 500 REMARK 500 REMARK: NULL REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1BXL RELATED DB: PDB REMARK 900 STRUCTURE OF BCL-XL/BAK PEPTIDE COMPLEX, NMR, MINIMIZED AVERAGE REMARK 900 STRUCTURE REMARK 900 RELATED ID: 1YSI RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF THE ANTI-APOPTOTIC PROTEIN BCL- XL INCOMPLEX REMARK 900 WITH AN ACYL-SULFONAMIDE-BASED LIGAND REMARK 900 RELATED ID: 2B48 RELATED DB: PDB REMARK 900 BCL-XL 3D DOMAIN SWAPPED DIMER REMARK 900 RELATED ID: 1R2E RELATED DB: PDB REMARK 900 HUMAN BCL-XL CONTAINING A GLU TO LEU MUTATION AT POSITION 92 REMARK 900 RELATED ID: 1YSG RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF THE ANTI-APOPTOTIC PROTEIN BCL- XL INCOMPLEX REMARK 900 WITH "SAR BY NMR" LIGANDS REMARK 900 RELATED ID: 1YSN RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF THE ANTI-APOPTOTIC PROTEIN BCL- XLCOMPLEXED REMARK 900 WITH AN ACYL-SULFONAMIDE-BASED LIGAND REMARK 900 RELATED ID: 1R2G RELATED DB: PDB REMARK 900 HUMAN BCL-XL CONTAINING A PHE TO TRP MUTATION AT POSITION 97 REMARK 900 RELATED ID: 1R2H RELATED DB: PDB REMARK 900 HUMAN BCL-XL CONTAINING AN ALA TO LEU MUTATION AT POSITION142 REMARK 900 RELATED ID: 1LXL RELATED DB: PDB REMARK 900 NMR STRUCTURE OF BCL-XL, AN INHIBITOR OF PROGRAMMED CELL DEATH, REMARK 900 MINIMIZED AVERAGE STRUCTURE REMARK 900 RELATED ID: 1R2D RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN BCL-XL AT 1.95 ANGSTROMS REMARK 900 RELATED ID: 1G5J RELATED DB: PDB REMARK 900 COMPLEX OF BCL-XL WITH PEPTIDE FROM BAD REMARK 900 RELATED ID: 1MAZ RELATED DB: PDB REMARK 900 X-RAY STRUCTURE OF BCL-XL, AN INHIBITOR OF PROGRAMMED CELL DEATH REMARK 900 RELATED ID: 1R2I RELATED DB: PDB REMARK 900 HUMAN BCL-XL CONTAINING A PHE TO LEU MUTATION AT POSITION146 REMARK 999 REMARK 999 SEQUENCE REMARK 999 N-TERMINAL AMINO ACID RESIDUES GPLGS ARE A RESULT OF A REMARK 999 CLONING ARTIFACT, DELETION OF AMINO ACID RESIDUES 27 TO 82 REMARK 999 AND 210 TO 233 DBREF 2YJ1 A 1 26 UNP Q07817 B2CL1_HUMAN 1 26 DBREF 2YJ1 A 83 209 UNP Q07817 B2CL1_HUMAN 83 209 DBREF 2YJ1 C 1 26 UNP Q07817 B2CL1_HUMAN 1 26 DBREF 2YJ1 C 83 209 UNP Q07817 B2CL1_HUMAN 83 209 DBREF 2YJ1 B 85 107 PDB 2YJ1 2YJ1 85 107 DBREF 2YJ1 D 85 107 PDB 2YJ1 2YJ1 85 107 SEQADV 2YJ1 GLY A -4 UNP Q07817 CLONING ARTIFACT SEQADV 2YJ1 PRO A -3 UNP Q07817 CLONING ARTIFACT SEQADV 2YJ1 LEU A -2 UNP Q07817 CLONING ARTIFACT SEQADV 2YJ1 GLY A -1 UNP Q07817 CLONING ARTIFACT SEQADV 2YJ1 SER A 0 UNP Q07817 CLONING ARTIFACT SEQADV 2YJ1 GLY C -4 UNP Q07817 CLONING ARTIFACT SEQADV 2YJ1 PRO C -3 UNP Q07817 CLONING ARTIFACT SEQADV 2YJ1 LEU C -2 UNP Q07817 CLONING ARTIFACT SEQADV 2YJ1 GLY C -1 UNP Q07817 CLONING ARTIFACT SEQADV 2YJ1 SER C 0 UNP Q07817 CLONING ARTIFACT SEQRES 1 A 158 GLY PRO LEU GLY SER MET SER GLN SER ASN ARG GLU LEU SEQRES 2 A 158 VAL VAL ASP PHE LEU SER TYR LYS LEU SER GLN LYS GLY SEQRES 3 A 158 TYR SER TRP SER GLN MET ALA ALA VAL LYS GLN ALA LEU SEQRES 4 A 158 ARG GLU ALA GLY ASP GLU PHE GLU LEU ARG TYR ARG ARG SEQRES 5 A 158 ALA PHE SER ASP LEU THR SER GLN LEU HIS ILE THR PRO SEQRES 6 A 158 GLY THR ALA TYR GLN SER PHE GLU GLN VAL VAL ASN GLU SEQRES 7 A 158 LEU PHE ARG ASP GLY VAL ASN TRP GLY ARG ILE VAL ALA SEQRES 8 A 158 PHE PHE SER PHE GLY GLY ALA LEU CYS VAL GLU SER VAL SEQRES 9 A 158 ASP LYS GLU MET GLN VAL LEU VAL SER ARG ILE ALA ALA SEQRES 10 A 158 TRP MET ALA THR TYR LEU ASN ASP HIS LEU GLU PRO TRP SEQRES 11 A 158 ILE GLN GLU ASN GLY GLY TRP ASP THR PHE VAL GLU LEU SEQRES 12 A 158 TYR GLY ASN ASN ALA ALA ALA GLU SER ARG LYS GLY GLN SEQRES 13 A 158 GLU ARG SEQRES 1 B 23 ACE HT7 ALA ARG B3E ILE GLY ALA B3Q LEU ARG HR7 MET SEQRES 2 B 23 ALA ASP B3D LEU ASN B3A GLN TYR GLU NH2 SEQRES 1 C 158 GLY PRO LEU GLY SER MET SER GLN SER ASN ARG GLU LEU SEQRES 2 C 158 VAL VAL ASP PHE LEU SER TYR LYS LEU SER GLN LYS GLY SEQRES 3 C 158 TYR SER TRP SER GLN MET ALA ALA VAL LYS GLN ALA LEU SEQRES 4 C 158 ARG GLU ALA GLY ASP GLU PHE GLU LEU ARG TYR ARG ARG SEQRES 5 C 158 ALA PHE SER ASP LEU THR SER GLN LEU HIS ILE THR PRO SEQRES 6 C 158 GLY THR ALA TYR GLN SER PHE GLU GLN VAL VAL ASN GLU SEQRES 7 C 158 LEU PHE ARG ASP GLY VAL ASN TRP GLY ARG ILE VAL ALA SEQRES 8 C 158 PHE PHE SER PHE GLY GLY ALA LEU CYS VAL GLU SER VAL SEQRES 9 C 158 ASP LYS GLU MET GLN VAL LEU VAL SER ARG ILE ALA ALA SEQRES 10 C 158 TRP MET ALA THR TYR LEU ASN ASP HIS LEU GLU PRO TRP SEQRES 11 C 158 ILE GLN GLU ASN GLY GLY TRP ASP THR PHE VAL GLU LEU SEQRES 12 C 158 TYR GLY ASN ASN ALA ALA ALA GLU SER ARG LYS GLY GLN SEQRES 13 C 158 GLU ARG SEQRES 1 D 23 ACE HT7 ALA ARG B3E ILE GLY ALA B3Q LEU ARG HR7 MET SEQRES 2 D 23 ALA ASP B3D LEU ASN B3A GLN TYR GLU NH2 MODRES 2YJ1 HT7 B 86 TRP MODRES 2YJ1 B3E B 89 GLU (3S)-3-AMINOHEXANEDIOIC ACID MODRES 2YJ1 HR7 B 96 ARG MODRES 2YJ1 B3D B 100 ASP 3-AMINOPENTANEDIOIC ACID MODRES 2YJ1 B3A B 103 ALA (3S)-3-AMINOBUTANOIC ACID MODRES 2YJ1 HT7 D 86 TRP MODRES 2YJ1 B3E D 89 GLU (3S)-3-AMINOHEXANEDIOIC ACID MODRES 2YJ1 HR7 D 96 ARG MODRES 2YJ1 B3D D 100 ASP 3-AMINOPENTANEDIOIC ACID MODRES 2YJ1 B3A D 103 ALA (3S)-3-AMINOBUTANOIC ACID HET HT7 B 86 15 HET B3E B 89 10 HET B3Q B 93 10 HET HR7 B 96 12 HET B3D B 100 9 HET B3A B 103 6 HET NH2 B 107 1 HET ACE D 85 1 HET HT7 D 86 15 HET B3E D 89 10 HET B3Q D 93 10 HET HR7 D 96 12 HET B3D D 100 9 HET B3A D 103 6 HETNAM HT7 (3S)-3-AMINO-4-(1H-INDOL-3-YL)BUTANOIC ACID HETNAM B3E (3S)-3-AMINOHEXANEDIOIC ACID HETNAM B3Q (3S)-3,6-DIAMINO-6-OXOHEXANOIC ACID HETNAM HR7 (3S)-3-AMINO-6-[(DIAMINOMETHYLIDENE)AMINO]HEXANOIC ACID HETNAM B3D 3-AMINOPENTANEDIOIC ACID HETNAM B3A (3S)-3-AMINOBUTANOIC ACID HETNAM NH2 AMINO GROUP HETNAM ACE ACETYL GROUP HETSYN HT7 BETA-HOMOTRYPTOPHAN HETSYN B3Q (S)-BETA-3-HOMOGLUTAMINE HETSYN HR7 BETA-HOMOARGININE HETSYN B3D BETA-HOMOASPARTATE FORMUL 2 HT7 2(C12 H14 N2 O2) FORMUL 2 B3E 2(C6 H11 N O4) FORMUL 2 B3Q 2(C6 H12 N2 O3) FORMUL 2 HR7 2(C7 H16 N4 O2) FORMUL 2 B3D 2(C5 H9 N O4) FORMUL 2 B3A 2(C4 H9 N O2) FORMUL 2 NH2 H2 N FORMUL 4 ACE C2 H4 O FORMUL 5 HOH *68(H2 O) HELIX 1 1 GLY A -1 GLN A 3 5 5 HELIX 2 2 SER A 4 LYS A 20 1 17 HELIX 3 3 SER A 25 TYR A 101 1 21 HELIX 4 4 TYR A 101 LEU A 112 1 12 HELIX 5 5 THR A 118 PHE A 131 1 14 HELIX 6 6 ASN A 136 LYS A 157 1 22 HELIX 7 7 VAL A 161 HIS A 177 1 17 HELIX 8 8 LEU A 178 ASN A 185 1 8 HELIX 9 9 GLY A 187 GLY A 196 1 10 HELIX 10 10 ILE B 90 ARG B 95 1 6 HELIX 11 11 MET C 1 GLN C 19 1 19 HELIX 12 12 SER C 25 TYR C 101 1 21 HELIX 13 13 TYR C 101 SER C 110 1 10 HELIX 14 14 THR C 118 PHE C 131 1 14 HELIX 15 15 ASN C 136 LYS C 157 1 22 HELIX 16 16 VAL C 161 LEU C 178 1 18 HELIX 17 17 LEU C 178 ASN C 185 1 8 HELIX 18 18 GLY C 187 TYR C 195 1 9 HELIX 19 19 ILE D 90 ARG D 95 1 6 LINK C HT7 B 86 N ALA B 87 1555 1555 1.33 LINK C ARG B 88 N B3E B 89 1555 1555 1.33 LINK C B3E B 89 N ILE B 90 1555 1555 1.32 LINK C ALA B 92 N B3Q B 93 1555 1555 1.33 LINK C B3Q B 93 N LEU B 94 1555 1555 1.33 LINK C ARG B 95 N HR7 B 96 1555 1555 1.33 LINK C HR7 B 96 N MET B 97 1555 1555 1.33 LINK C ASP B 99 N B3D B 100 1555 1555 1.33 LINK C B3D B 100 N LEU B 101 1555 1555 1.33 LINK C ASN B 102 N B3A B 103 1555 1555 1.33 LINK C B3A B 103 N GLN B 104 1555 1555 1.33 LINK C GLU B 106 N NH2 B 107 1555 1555 1.33 LINK C ACE D 85 N HT7 D 86 1555 1555 1.33 LINK C HT7 D 86 N ALA D 87 1555 1555 1.33 LINK C ARG D 88 N B3E D 89 1555 1555 1.33 LINK C B3E D 89 N ILE D 90 1555 1555 1.33 LINK C ALA D 92 N B3Q D 93 1555 1555 1.34 LINK C B3Q D 93 N LEU D 94 1555 1555 1.32 LINK C ARG D 95 N HR7 D 96 1555 1555 1.33 LINK C HR7 D 96 N MET D 97 1555 1555 1.33 LINK C ASP D 99 N B3D D 100 1555 1555 1.33 LINK C B3D D 100 N LEU D 101 1555 1555 1.33 LINK C ASN D 102 N B3A D 103 1555 1555 1.33 LINK C B3A D 103 N GLN D 104 1555 1555 1.33 CRYST1 58.918 71.382 75.605 90.00 90.00 90.00 P 21 21 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.016973 0.000000 0.000000 0.00000 SCALE2 0.000000 0.014009 0.000000 0.00000 SCALE3 0.000000 0.000000 0.013227 0.00000